Biontech Covid-19 Vaccine
- All
- News
- Videos
-
What Are mRNA Vaccines That Earned Two Scientists Nobel Prize In Medicine?
This year's Nobel Prize in Medicine has been awarded to scientists for discoveries that enabled the development of mRNA vaccines against COVID-19.
-
World "Better Prepared" For Covid Variants: Vaccine Maker BioNTech
The world is becoming "better prepared" to deal with future variants of the coronavirus, the CEO and co-founder of German vaccine-maker BioNTech told AFP Thursday, as the company works on an Omicron-specific shot.
-
Pfizer To Seek US Approval For Covid Vaccine For Children Under 5: Report
Pfizer and BioNTech will soon ask US regulators for emergency authorization for a Covid-19 vaccine for children aged five and under, US media reported Tuesday.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Shots Should Protect From Worst Of Omicron, Says Big Vaccine-Maker
The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.
-
BioNTech Is Working On An 'Omicron' Version Of Its Covid Shot
BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.
-
Pfizer Vaccine 100% Effective In Adolescents After 4 Months
Pfizer and BioNTech said Monday their COVID-19 vaccine remained 100 percent effective in children 12 to 15 years old, four months after the second dose.
-
Pfizer Requests US Emergency Authorisation For Covid Booster For Adults
Drugmakers Pfizer and BioNTech announced Tuesday they have formally submitted a request asking US officials for emergency authorization of their Covid-19 booster vaccine for people aged 18 and older.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
US To Weigh Authorisation Of Pfizer Covid Vaccine For Children Aged 5-11
An expert panel will weigh authorization of Pfizer Inc and BioNTech's COVID-19 vaccine for children aged 5 to 11 on Tuesday as it prepares to vote on a recommendation for the US Food and Drug Administration.
-
Third Dose Of Pfizer's COVID-19 Vaccine 95.6% Effective: Study
A third dose of the vaccine against COVID-19 developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
-
What Are mRNA Vaccines That Earned Two Scientists Nobel Prize In Medicine?
This year's Nobel Prize in Medicine has been awarded to scientists for discoveries that enabled the development of mRNA vaccines against COVID-19.
-
World "Better Prepared" For Covid Variants: Vaccine Maker BioNTech
The world is becoming "better prepared" to deal with future variants of the coronavirus, the CEO and co-founder of German vaccine-maker BioNTech told AFP Thursday, as the company works on an Omicron-specific shot.
-
Pfizer To Seek US Approval For Covid Vaccine For Children Under 5: Report
Pfizer and BioNTech will soon ask US regulators for emergency authorization for a Covid-19 vaccine for children aged five and under, US media reported Tuesday.
-
Pfizer-BioNTech Begin Trials For An Omicron-Specific Vaccine
Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.
-
Pfizer Shots, Prior Infection May Protect Better vs Omicron: Scientists
A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.
-
Omicron Scare: Pfizer Says Third Dose Key To Fight Spread
Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec
-
For Omicron, Third Dose Of Covid Shot May Be Needed: Pfizer
Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.
-
Shots Should Protect From Worst Of Omicron, Says Big Vaccine-Maker
The current generation of Covid-19 vaccines probably will still protect against severe disease in people infected by the omicron variant, BioNTech SE Chief Executive Officer Ugur Sahin said.
-
BioNTech Is Working On An 'Omicron' Version Of Its Covid Shot
BioNTech SE is working to adapt its Covid-19 vaccine to address the 'Omicron' variant and expects to have a new version ready within 100 days if necessary.
-
Pfizer Vaccine 100% Effective In Adolescents After 4 Months
Pfizer and BioNTech said Monday their COVID-19 vaccine remained 100 percent effective in children 12 to 15 years old, four months after the second dose.
-
Pfizer Requests US Emergency Authorisation For Covid Booster For Adults
Drugmakers Pfizer and BioNTech announced Tuesday they have formally submitted a request asking US officials for emergency authorization of their Covid-19 booster vaccine for people aged 18 and older.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
US To Weigh Authorisation Of Pfizer Covid Vaccine For Children Aged 5-11
An expert panel will weigh authorization of Pfizer Inc and BioNTech's COVID-19 vaccine for children aged 5 to 11 on Tuesday as it prepares to vote on a recommendation for the US Food and Drug Administration.
-
Third Dose Of Pfizer's COVID-19 Vaccine 95.6% Effective: Study
A third dose of the vaccine against COVID-19 developed by Pfizer/BioNTech is 95.6 percent effective against symptomatic infection.
-
Covid Protection Wanes Months After Second Shot, Booster Needed: Study
Immunity provided by the Covid-19 vaccine from partners Pfizer Inc. and BioNTech SE weakens significantly within months, with men having less protection than women, according to research that supports the use of booster doses.
